Provention Bio Announces Change to a Virtual Meeting Format for the 2020 Annual Meeting of the Stockholders
June 30, 2020

OLDWICK, N.J., June 30, 2020 /PRNewswire/ -- Provention Bio, Inc., (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, announced today a change in the format of its 2020 Annual Meeting of Stockholders (the "Annual Meeting") from in-person to a virtual-only meeting format due to the continuing public health impact of COVID-19 and to support the health and safety of the Company's stockholders and attendees. As previously announced, the Annual Meeting will be held on Wednesday, July 15 at 9:00 a.m. Eastern Time ("ET").

If you were a stockholder of record at the close of business on May 22, 2020, the Company's record date, or you hold a valid proxy for the Annual Meeting, you can vote at the Annual Meeting at

A summary of the information you need to attend the Annual Meeting is provided below:

  • Instructions on how to attend and participate via the Internet, including how to demonstrate proof of stock ownership, will be posted at;
  • Assistance with questions regarding how to attend and participate via the Internet will be provided at on the day of the Annual Meeting;
  • Stockholders may vote and submit questions on the day of and while attending the Annual Meeting via the Internet;
  • You will need your 16-Digit Control Number (provided to you in your proxy materials) to enter the Annual Meeting; and
  • The proxy materials for the Annual Meeting are available at

We encourage you to access the Annual Meeting 10 minutes prior to the start time. Online check-in will begin at 8:50 a.m. ET. We will have technicians ready to assist you with any technical difficulties before the virtual Annual Meeting begins on the day of the Annual Meeting at

About Provention Bio, Inc.
Provention Bio, Inc. (Nasdaq: PRVB) is a biopharmaceutical company leveraging a transformational drug development strategy focused on the prevention or interception of immune-mediated disease. Provention's mission is to source, transform and develop therapeutic candidates targeting the high morbidity, mortality and escalating costs of autoimmune diseases. Provention's diversified portfolio includes teplizumab, a pre-commercial-stage candidate that has been shown to delay the onset of insulin-dependent type 1 diabetes (T1D) in at-risk patients during the presymptomatic phase of the disease. The Company's portfolio includes additional clinical product development candidates that have demonstrated proof-of-mechanism and/or proof-of-concept in other autoimmune diseases, including celiac disease and lupus.

Investor Contact:
Sam Martin, Argot Partners 

Lori Rosen, LDR Communications


SOURCE Provention Bio, Inc.